Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine

References

• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. doi: 10.1182/blood.2022016867
   PubMed Web of Science ®Google Scholar
• Prassek VV, Rothenberg-Thurley M, Sauerland MC, et al. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica. 2018;103(11):1853–1861. doi: 10.3324/haematol.2018.191536
   PubMed Web of Science ®Google Scholar
• Park E-H, Lee H, Won Y-J, et al. Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012. Br. 2015;50(4):204–217.
   Google Scholar
• Shin D-Y. Human acute myeloid leukemia stem cells: evolution of concept. Blood Res. 2022;57:S67–S74.
   Web of Science ®Google Scholar
• Erba HP. Prognostic factors in elderly patients with AML and the implications for treatment. ASH Education Program Book. 2007;2007(1):420–428.
   Google Scholar
• Kim DH, Byun JM, Shin DY, et al. Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm. Blood Res. 2023;58(3):155–157. doi: 10.5045/br.2023.2023136
   Web of Science ®Google Scholar
• Short NJ, Konopleva M, Kadia TM, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10(4):506–525. doi: 10.1158/2159-8290.CD-19-1011
   PubMed Web of Science ®Google Scholar
• Wu RH, Zhu CY, Yu PH, et al. The landscape of novel strategies for acute myeloid leukemia treatment: therapeutic trends, challenges, and future directions. Toxicol Appl Pharmacol. 2023;473:116585. doi: 10.1016/j.taap.2023.116585
   Web of Science ®Google Scholar
• Yilmaz M, Kantarjian H, Short NJ, et al. Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022;12(5):77. doi: 10.1038/s41408-022-00670-0
   Web of Science ®Google Scholar
• Wang QQ, Wang HF, Zhao JZ, et al. Venetoclax for arsenic-resistant acute promyelocytic leukaemia. Br J Haematol. 2022;197(5):e58–e60.
   Web of Science ®Google Scholar
• Ahn J-S, Kim H-J. FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs. Blood Res. 2022;57:S32–S36.
   Web of Science ®Google Scholar
• Byun JM, Yoo S-J, Kim H-J, et al. IDH1/2 mutations in acute myeloid leukemia. Blood Res. 2022;57(1):13–19. doi: 10.5045/br.2021.2021152
   Google Scholar
• Konopleva M, Thirman MJ, Pratz KW, et al. Impact of FLT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naïve acute myeloid leukemia. Clin Cancer Res. 2022;28(13):2744–2752. doi: 10.1158/1078-0432.CCR-21-3405
   Web of Science ®Google Scholar
• Ohanian M, Garcia-Manero G, Levis M, et al. Sorafenib combined with 5-azacytidine in older patients with untreatedFLT3-ITD mutated acute myeloid leukemia. Am J Hematol. 2018;93(9):1136–1141. doi: 10.1002/ajh.25198
   PubMed Web of Science ®Google Scholar
• Ossenkoppele G, Löwenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125(5):767–774. doi: 10.1182/blood-2014-08-551499
   PubMed Web of Science ®Google Scholar
• Klepin HD. Elderly acute myeloid leukemia: assessing risk. Curr Hematol Malig Rep. 2015;10(2):118–125. doi: 10.1007/s11899-015-0257-2
   PubMed Web of Science ®Google Scholar
• Rao AV, Valk PJ, Metzeler KH, et al. Age-Specific differences in oncogenic pathway dysregulation in patients With acute myeloid leukemia. J Clin Oncol. 2009;27(33):5580–5586. doi: 10.1200/JCO.2009.22.2547
   PubMed Web of Science ®Google Scholar
• Wang ES. Treating acute myeloid leukemia in older adults. Hematology. 2014;2014(1):14–20.
   Google Scholar
• Hourigan CS, Karp JE. Development of therapeutic agents for older patients with acute myelogenous leukemia. Curr Opin Investig Drugs. 2010;11(6):669–677.
   PubMedGoogle Scholar
• Hwang SM. Bibliometric analysis of studies about acute myeloid leukemia conducted globally from 1999 to 2018. Blood Res. 2020;55(S1):1–9. doi: 10.5045/br.2020.55.1.1
   PubMedGoogle Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi: 10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Wang B, Liu Y, Hou G, et al. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing. Oncotarget. 2016;7(22):32065–32078.
   Google Scholar
• Döhner K, Thiede C, Jahn N, et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020;135(5):371–380. doi: 10.1182/blood.2019002697
   PubMed Web of Science ®Google Scholar
• Sierra J, Nomdedeu JF. CEBPA bZip mutations: just a single shot. Blood. 2021;138(13):1091–1092. doi: 10.1182/blood.2021011263
   Web of Science ®Google Scholar
• Taube F, Georgi JA, Kramer M, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2022;139(1):87–103. doi: 10.1182/blood.2020009680
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. doi: 10.1056/NEJMoa1516192
   PubMed Web of Science ®Google Scholar
• Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074. doi: 10.1056/NEJMoa1301689
   PubMed Web of Science ®Google Scholar
• Kang L, Chen W, Petrick NA, et al. Assessing correlation of clustered mixed outcomes from a multivariate generalized linear mixed model. Stat Med. 2015;34(4):704–720. doi: 10.1002/sim.6374
   Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB, Steyerberg EW. Editorial. Stat Med. 2011;30(1):11–21. doi: 10.1002/sim.4183
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi: 10.1038/bmt.2012.244
   PubMed Web of Science ®Google Scholar
• Molica M, Mazzone C, Niscola P, et al. Identification of predictive factors for overall survival and response during hypomethylating treatment in very elderly (≥75 years) acute myeloid leukemia patients: a multicenter real-life experience. Cancers (Basel). 2022;14(19):4897.
   Web of Science ®Google Scholar
• Mrózek K, Kohlschmidt J, Blachly JS, et al. Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study. Leukemia. 2023;37(4):788–798. doi: 10.1038/s41375-023-01846-8
   Web of Science ®Google Scholar
• Schnittger S, Bacher U, Kern W, et al. Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics. Leukemia. 2011;25(8):1361–1364. doi: 10.1038/leu.2011.80
   Web of Science ®Google Scholar
• Pratcorona M, Brunet S, Nomdedéu J, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013;121(14):2734–2738. doi: 10.1182/blood-2012-06-431122
   PubMed Web of Science ®Google Scholar
• Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776–2784. doi: 10.1182/blood-2007-08-109090
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Yamaguchi H, Najima Y, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv. 2018;2(20):2744–2754. doi: 10.1182/bloodadvances.2018020305
   PubMed Web of Science ®Google Scholar
• Palmieri R, Paterno G, De Bellis E, et al. Therapeutic choice in older patients with acute myeloid leukemia: a matter of fitness. Cancers (Basel). 2020;12(1):120.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi: 10.1056/NEJMoa2012971
   PubMed Web of Science ®Google Scholar
• Montalban-Bravo G, Kanagal-Shamanna R, Class CA, et al. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020;95(6):612–622. doi: 10.1002/ajh.25769
   PubMed Web of Science ®Google Scholar
• Yoshizato T, Nannya Y, Atsuta Y, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood. 2017;129(17):2347–2358. doi: 10.1182/blood-2016-12-754796
   PubMed Web of Science ®Google Scholar
• Rausch C, Rothenberg-Thurley M, Dufour A, et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023;37(6):1234–1244. doi: 10.1038/s41375-023-01884-2
   Web of Science ®Google Scholar
• Koenig KL, Sahasrabudhe KD, Sigmund AM, et al. Aml with myelodysplasia-related changes: development, challenges, and treatment advances. Genes (Basel). 2020;11(8):845. doi: 10.3390/genes11080845
   PubMed Web of Science ®Google Scholar
• Song GY, Kim T, Ahn SY, et al. Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia. Bone Marrow Transplant. 2022;57(12):1810–1819. doi: 10.1038/s41409-022-01817-0
   Web of Science ®Google Scholar